Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa (NCT07049575)

🧪 Interventions in This Study

• Ruxolitinib Cream (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Diagnosis of HS for at least 6 months before screening visit.
2. Diagnosis of HS (Hurley Stage I, II, III) with a total abscess and inflammatory nodule count of at least 4 and affecting at least 3 distinct anatomical areas at screening and Day 1 visits.
3. Total estimated treatment BSA \> 20% at screening and baseline.
4. Agreement to not use topical or systemic antibiotics for treatment of HS during the Maximal Use Treatment Period.
5. Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol.
6. Further inclusion criteria apply.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (21 Sites)

• Saguaro Dermatology — Phoenix, Arizona
• First Oc Dermatology — Fountain Valley, California
• Amicis Research Center Valencia — Northridge, California
• Children'S Hospital of Orange County — Orange, California
• Clinical Trials Research Institute — Thousand Oaks, California
• Clarity Dermatology — Castle Rock, Colorado
• International Clinical Research Tennessee Llc — Sanford, Florida
• Lenus Research Medical Group, Llc — Sweetwater, Florida
• Trueblue Clinical Research — Tampa, Florida
• Lane Dermatology and Dermatologic Surgery — Columbus, Georgia
• Options Research Group, Llc — West Lafayette, Indiana
• Equity Medical, Llc — Bowling Green, Kentucky
• Delricht Research — Baton Rouge, Louisiana
• Revival Research Institute, Llc Troy — Troy, Michigan
• Red River Research Partners — Bolivar, Missouri
• Dr Bobby Buka, Md Greenwich Village — New York, New York
• Equity Medical, Llc — New York, New York
• Red River Research Partners — Fargo, North Dakota
• Centricity Research Columbus — Columbus, Ohio
• Unity Clinical Research — Oklahoma City, Oklahoma
• Paddington Testing Co Inc — Philadelphia, Pennsylvania

📞 Contact the Study Coordinator

Phone: (855) 463-3463

Email: medinfo@incyte.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hidradenitis Suppurativa

• Real-world Secukinumab Outcomes in Canadian HS Patients — Calgary, Alberta
• A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. — Phoenix, Arizona
• A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy — Phoenix, Arizona
• Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa. — Birmingham, Alabama
• Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository — San Francisco, California

Explore by condition: All Hidradenitis Suppurativa clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.